Vetr Inc. announced Kite Pharma Inc (NASDAQ:KITE), boosting its stock price target to $64.48 today
- Updated: October 12, 2016
Just yesterday Kite Pharma Inc (NASDAQ:KITE) traded -6.70% lower at $51.07. Kite Pharma Inc’s 50-day moving average is $56.79 and its 200-day moving average is $52.36. The last stock price is down -1.34% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 817,909 shares of KITE traded hands, down from an average trading volume of 855,814
In a report released on 10/12/2016 Vetr Inc. increased the stock price target of Kite Pharma Inc (NASDAQ:KITE) to $64.48 reporting a possible upside of 0.26%.
Previously on 09/27/2016, Barclays Capital released a statement about Kite Pharma Inc (NASDAQ:KITE) increased the target price from $60.00 to $65.00. At the time, this indicated a possible upside of 0.09%.
Recent Performance Chart
Kite Pharma Inc has 52 week low of $38.41 and a 52 week high of $89.84 and has a market capitalization of $0.
In addition to Vetr Inc. reporting its stock price target, a total of 11 brokerages have issued a ratings update on the company. The average stock price target is $74.18 with 6 brokerages rating the stock a strong buy, 7 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Kite Pharma Inc (NASDAQ:KITE)
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.